Asked to organize an international meeting on Propafenone (Ryt monorm) we had to question ourselves, whether to accept this offer just as interested physicians or in our capacity as chairmen of the study group on arrhythmias and intracardiac electrography of the European Society of Cardiology. Considerung the "pros and contras" and well aware that one can easily be regarded as "product promoter" we, nevertheless, choose to organize the Symposion in association with the study group. We felt justified to do so for a number of reasons: Arrhyth mias and their treatment as well as the tools to detect the first and to control the latter are well within the scope of the study group. An international symposion provided the opportunity to have the "state of the art" in arrhythmias and antiarrhythmic treatment thoroughly reviewed by internationally renowned investigators, thus serving an educational purpose. Furthermore it was the intention and aim of the meeting to have what is known about a fairly new drug presented in a critical manner and to point out what is not known, but should be known. It is in that context the presentations of the free session should be judged. To the careful reader it will become apparent that much which was not said, can be read "between the lines".
